Ifosfamide induced encephalopathy in a child with osteosarcoma
dc.contributor.author | Sarbay, H. | |
dc.contributor.author | Demir, Ü.F. | |
dc.contributor.author | Yılmaz, G. | |
dc.contributor.author | Atay, A.A. | |
dc.contributor.author | Malbora, B. | |
dc.date.accessioned | 2021-12-21T08:40:30Z | |
dc.date.available | 2021-12-21T08:40:30Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 10781552 | |
dc.identifier.uri | https://doi.org/10.1177/1078155220963545 | |
dc.identifier.uri | http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1027 | |
dc.description.abstract | Background: Ifosfamide (IFO) is an alkylating agent used to treat broad range of malignancies. One of the life-threatening toxic effects is reversible neurotoxicity. In this report; we presented a case report of ifosfamide induced encephalopathy (IIE) in | |
dc.language.iso | English | |
dc.publisher | SAGE Publications Ltd | |
dc.title | Ifosfamide induced encephalopathy in a child with osteosarcoma | |
dc.type | Article | |
dc.relation.journal | Journal of Oncology Pharmacy Practice | |
dc.identifier.issue | 5 | |
dc.identifier.startpage | 1302 | |
dc.identifier.endpage | 1306 | |
dc.identifier.volume | 27 | |
dc.identifier.doi | 10.1177/1078155220963545 | |
dc.relation.issue | 5 | |
dc.relation.volume | 27 |
Bu öğenin dosyaları:
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |